Literature DB >> 15287037

Supraglottic hemipharyngolaryngectomy for the treatment of T1 and T2 carcinomas of laryngeal margin and piriform sinus.

Marc Makeieff1, Guiseppe Mercante, Elhám Jouzdani, Renaud Garrel, Louis Crampette, Bernard Guerrier.   

Abstract

BACKGROUND: We evaluated the functional and oncologic results of supraglottic hemipharyngolaryngectomy as treatment for T1 and T2 lateral laryngeal margin and piriform sinus carcinomas.
METHODS: Eighty-seven patients underwent this surgical treatment. The disease was classified T1 in 14 of these cases (16.1%) and T2 in 73 cases (83.9%). The nodal status indicated 39 cases of N0 (44.8%), 18 cases of N1 (20.7%), 28 cases of N2 (32.2%), and two cases of N3 (2.2%). With regard to the N0 cases, 15 (38.4%) were positive at the histologic examination. Within the N+ group, 52.1% involved capsular rupture.
RESULTS: Two patients died of complications during the postoperative period. The mean duration of nasogastric tube feeding was 20 days. Six patients (7.27%) had feeding resumption problems. All patients were decanulated after a mean period of 16 days. All patients underwent postoperative radiation therapy, except two with T1N0N- disease and three who had previously undergone this treatment. The 5-year actuarial survival rate was 60.3% (T1, 83.3%; T2, 49.9%). The rates of local and regional recurrence, second primary cancer, and metastasis were 19.5%, 24.1%, and 28.1%, respectively. The infringement of the pharyngoepiglottic fold was significantly correlated with locoregional recurrence. The survival rate was significantly correlated with the nodal status and extracapsular spread.
CONCLUSIONS: Initial staged cancers of the laryngeal margin and piriform sinus can be successfully managed with conservative surgery called supraglottic hemipharyngolaryngectomy combined with nodal neck dissection. Postoperative radiation therapy is still recommended in most cases because of the high recurrence potential and prevalence of secondary regional cancers. This combined treatment seems to be a suitable therapeutic choice in the treatment of patients with T1 and T2 carcinomas of the laryngeal margins and piriform sinus. Copyright 2004 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15287037     DOI: 10.1002/hed.20051

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  7 in total

1.  Primary radiotherapy for squamous cell carcinoma of the pyriform sinus.

Authors:  William M Mendenhall; Robert J Amdur; Christopher G Morris; Jessica Kirwan; Peter T Dziegielewski; John W Werning
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-14       Impact factor: 2.503

2.  Oncological and functional outcomes of transoral laser surgery for hypopharyngeal carcinoma.

Authors:  Rodrigo Casanueva; Fernando López; Patricia García-Cabo; César Álvarez-Marcos; José Luis Llorente; Juan Pablo Rodrigo
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-09-03       Impact factor: 3.236

3.  Functional organ preservation in laryngeal and hypopharyngeal cancer.

Authors:  Petra Ambrosch; Asita Fazel
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-04-26

4.  Early hypopharyngeal cancer treated with different therapeutic approaches: a single-institution cohort analysis.

Authors:  Nalee Kim; Jeongshim Lee; Kyung Hwan Kim; Jong Won Park; Chang Geol Lee; Ki Chang Keum
Journal:  Radiat Oncol J       Date:  2016-10-31

5.  Oncological and Functional Evaluation of Open Conservation Surgery for Hypopharyngeal Cancer with/without Reconstruction.

Authors:  Tsutomu Nomura; Daisuke Maki; Sadahiro Kishishita; Fumihiko Matsumoto; Seiichi Yoshimoto
Journal:  Int J Otolaryngol       Date:  2018-03-26

6.  Traditional transcutaneous approaches in head and neck surgery.

Authors:  Ulrich R Goessler
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-12-20

7.  Radiotherapy for stage I or II hypopharyngeal carcinoma.

Authors:  Hideki Nishimura; Ryohei Sasaki; Kenji Yoshida; Daisuke Miyawaki; Yoshiaki Okamoto; Naomi Kiyota; Miki Saito; Naoki Otsuki; Ken-ichi Nibu
Journal:  J Radiat Res       Date:  2012-09-17       Impact factor: 2.724

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.